SubHero Banner

Ravicti® (glycerol phenylbutyrate) – Expanded indication

May 1, 2017 – Horizon Pharma announced the FDA approval of Ravicti (glycerol phenylbutyrate) oral liquid, for chronic management of patients 2 months of age and older with urea cycle disorders (UCDs) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone.

Download PDF